Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Neurosense Therapeutics Ltd. (NRSN:NASDAQ), powered by AI.
Neurosense Therapeutics Ltd. is currently trading at $0.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Neurosense Therapeutics Ltd. on Alpha Lenz.
Neurosense Therapeutics Ltd.'s P/E ratio is -1.6.
“Neurosense Therapeutics Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -2175.0%.”
Ask for details →Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases. Focusing primarily on targeting conditions like Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and Parkinson's disease, Neurosense leverages cutting-edge research to formulate therapeutic solutions that can address unmet medical needs. The company's research and development are rooted in a deep understanding of disease mechanisms, aiming to offer novel drug compounds that can alter the course of debilitating neurodegenerative disorders. Neurosense Therapeutics collaborates with academic institutions and research organizations to validate its scientific approaches, positioning itself as a significant player in the biotechnology sector. By advancing its drug candidates through rigorous clinical trials, the company aims to provide new hope for patients affected by these challenging diseases. Neurosense Therapeutics contributes to the global healthcare landscape by striving to deliver breakthroughs that could potentially improve quality of life for millions of patients worldwide.
“Neurosense Therapeutics Ltd. trades at a P/E of -1.6 (undervalued) with modest ROE of -2175.0%.”
Ask for details →Neurosense Therapeutics Ltd. (ticker: NRSN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 17 employees. Market cap is $18M.
The current price is $0.699 with a P/E ratio of -1.6x and P/B of -11.42x.
ROE is -2174.98%.